Imunon Inc. has published a document detailing a Phase I/II study on the safety and efficacy of the investigational product IMNN-001, in combination with standard of care treatment, for patients newly diagnosed with advanced epithelial ovarian cancer. The document provides updated survival analysis from the OVATION-2 trial, highlighting the study's primary and secondary endpoints, including safety, progression-free survival, overall survival, and response rates. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.